Can we dramatically reduce the incidence of coronary heart disease?

Nature Reviews Cardiology

Volumn 8, Issue 12, 2011, Pages 721-725

  Domanski, Michael ^a   Lloyd Jones, Donald ^b   Fuster, Valentin ^a   Grundy, Scott ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

CAROTID ATHEROSCLEROSIS; FEASIBILITY STUDY; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; POINT MUTATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; STROKE;

ADULT; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; PREVENTIVE HEALTH SERVICES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 82255192241     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.158     Document Type: Review

References (32)

1. Fuster, V., Kelly, B. B. & Vedanthan, R. Promoting global cardiovcascualr heath: moving forward. Circulation 123, 1671-1678 (2011).
2. List of wars and anthropogenic disasters by death toll. Wikipedia online http://en.wikipedia.org/wiki/List-of-wars-and- anthropogenic-disasters-by-death- toll (2011).
3. Heidenreich, P. A. et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123, 933-944 (2011).
4. O'Keefe. J. H. Jr, Cordain, L., Harris, W. H., Moe, R. M. & Vogel, R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J. Am. Coll. Cardiol. 43, 2142-2146 (2004). (Pubitemid 38686815)
5. Chen, Z. et al. Serum cholesterol concentration and coronary heart disease in populations with low cholesterol concentrations. BMJ 303, 276-282 (1991).
6. Stamler, J., Wentworth, D. & Neaton, J. D. Is relationship between serum cholesterol and the risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MrFIT). JAMA 256, 2823-2828 (1986). (Pubitemid 17178359)
7. Stamler, J. Population studies. In Nutrition, Lipids, and Coronary Heart Disease: A Global View (eds Levy, R. I. et al) 25-88 (Raven, New York, 1979).
8. Prospective Studies Collaboration et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 370, 1829-1839 (2007).
9. Brown M. S. & Goldstein, J. L. Biomedicine. Lowering LDL-not only how low, but how long? Science 311, 1721-1723 (2006).
10. Eaton, S. B., Konner, M. & Shostak, M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am. J. Med. 84, 739-749 (1988).
11. Vint, F. W. Post-mortem findings in the natives of Kenya. E. Afr. Med. J. 13, 332-340 (1937).
12. Ho, K. J., Biss, K., Mikkelson, B., Lewis, L. A. & Taylor, C. B. The Masai of East Africa: some unique biological characteristics. Arch. Pathol. 91, 387-410 (1971).
13. Kato, H., Tillotson, J. Nichaman, M. Rhoads, G. G. & Hamilton, H. B. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California. Am. J. Epidemiol. 97, 372-385 (1973).
14. Truswell, A. S. & Hansen, D. L. Medical research among the !Kung. In Kalahari hunter-gatherers: studies of the !Kung San and their neighbours (eds Lee, R. B. & DeVore, I.) 166-195 (Harvard University Press, Cambridge, 1976).
15. No authors listed. The Lipid Research Clinics Coronary Primary Prevention Trial Results I. Reduction in incidence of coronary heart disease. JAMA 251, 351-364 (1984).
16. Frick, M. H. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987). (Pubitemid 17147964)
17. Ford, I. et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med. 357, 1477-1486 (2007). (Pubitemid 47572633)
18. Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCaPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615-1622 (1998). (Pubitemid 28248586)
19. Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149-1158 (2003). (Pubitemid 36398384)
20. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
21. Hsia, J., MacFadyen, B., Monyak, J. & Ridker, P. Cardiovascular event reduction and adverse events among subjects attaining low-density lipotrotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J. Am. Coll. Cardiol. 57, 1666-1675 (2011).
22. No authors listed. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. The ARIC investigators. Am. J. Epidemiol. 129, 687-702 (1989).
23. Cohen, J. C., Boerwinkle, E., Mosley T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
24. Frontini, M. et al. Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics 121, 924-929 (2008).
25. Law, M. R., Wald, N. J. & Rubnicka, A. R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326, 1423-1429 (2003).
26. DeMaria, A. N. et al. Comparative efficacy of strategies for risk screening and prevention for cardiovascular disease. J. Am. Coll. Cardiol. 53, A220 (2009).
27. Diamond, G. A. & Kaul, S. The things to come of SHAPE: cost and effectiveness of cardiovascular prevention. Am. J. Cardiol. 99, 1013-1015 (2007). (Pubitemid 46483296)
28. Kazmin, A., Garcia-Bournissen, F. Koren, G. Risks of statin use during pregnancy: a systematic review. J. Obstet. Gynaecol. Can. 29, 906-908 (2007).
29. D'Agostino, R. B. Sr et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743-753 (2008). (Pubitemid 351640675)
30. Berry, J. D. et al. Remaining lifetime risks for cardiovascular disease by age and risk factor burden: the cardiovascular lifetime risk pooling project. N. Engl. J. Med (in press).
31. Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
32. Cholesterol Treatment Trialists' (CTT) Collaborators et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 (2008).